(Q45164435)

10 December 2017

title

Risk factors for hepatocellular carcinoma in Hepatitis C patients with sustained virologic response to interferon therapy (English)

1 reference

10 December 2017

0 references

hepatocellular carcinoma

1 reference

Yoshiaki Iwasaki

1

1 reference

10 December 2017

Kouichi Takaguchi

2

1 reference

10 December 2017

Hiroshi Ikeda

3

1 reference

10 December 2017

Yasuhiro Makino

4

1 reference

10 December 2017

Yasuyuki Araki

5

1 reference

10 December 2017

Masaharu Ando

6

1 reference

10 December 2017

Haruhiko Kobashi

7

1 reference

10 December 2017

Toshitsugu Kobatake

8

1 reference

10 December 2017

Ryoji Tanaka

9

1 reference

10 December 2017

Minoru Tomita

10

1 reference

10 December 2017

Tomonori Senoh

11

1 reference

10 December 2017

Mitsuhiko Kawaguchi

12

1 reference

10 December 2017

Toshinari Shimoe

13

1 reference

10 December 2017

Koji Manabe

14

1 reference

10 December 2017

Keiji Kita

15

1 reference

10 December 2017

Junnosuke Shimamura

16

1 reference

10 December 2017

Kohsaku Sakaguchi

17

1 reference

10 December 2017

Yasushi Shiratori

18

1 reference

10 December 2017

publication date

1 December 2004

1 reference

10 December 2017

1 reference

10 December 2017

volume

24

1 reference

10 December 2017

issue

6

1 reference

10 December 2017

page(s)

603-610

1 reference

Characteristic difference of hepatocellular carcinoma between hepatitis B- and C- viral infection in Japan

10 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0956.X

Spontaneous negativation of serum hepatitis C virus RNA is a rare event in type C chronic liver diseases: analysis of HCV RNA in 320 patients who were followed for more than 3 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0956.X

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0956.X

Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0956.X

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0956.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0956.X

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0956.X

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0956.X

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0956.X

Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0956.X

Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0956.X

Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0956.X

Determinants of outcome of compensated hepatitis C virus-related cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0956.X

Significance of serum hepatitis C virus RNA levels in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0956.X

Significance of specific antibody assay for genotyping of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0956.X

Classification of chronic hepatitis: diagnosis, grading and staging

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0956.X

Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0956.X

Long-term follow-up of sustained responders to interferon therapy, in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0956.X

Analysis of hepatocellular carcinoma tumor growth detected in sustained responders to interferon in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0956.X

Genetic mechanisms of hepatocarcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0956.X

10.1111/J.1478-3231.2004.0956.X

21 January 2018

Identifiers

DOI

1 reference

10 December 2017

1 reference